Zila, Inc. (ZILAD) Retains William Blair & Company to Review Strategic Alternatives
More News related to ZILAD
- Zila, Inc. (ZILAD) Reports a Q4 Loss
- Trading Radar for 10/6: IDT Corp. (IDT), Zila (ZILAD) Report
- Zila, Inc. (ZILAD) Retains William Blair & Company to Review Strategic Alternatives
More News related to Corporate News
- Morning Movers 11/10: UPG, CYD, PCLN, FLL, BZH Higher; RHIE, OPXT, PRKR, PIKE, MBI, SDTH Lower
- Notable Mergers and Acquisitions of the Day 11/10: HSC
- After-Hours Movers 11/09: SGK, PCLN, SQNM Higher; MBI, SDTH, UTK, TOPS, CPST, BTN, FLR Lower
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Unusual 11 Mid-Day Movers 11/09: EONC, EWBC, REV, PRST Higher; GTN, CHNG, SRZ, CHDX Lower
Zila, Inc. (NASDAQ: ZILAD) has retained investment bank William Blair & Company to assist it in exploring strategic business opportunities.
"In recent months, we have established a solid foundation upon which to grow our business by reducing expenses, restructuring our operations and adding new international markets for ViziLite(R) Plus," said David Bethune, chairman and chief executive officer of Zila. "The engagement of William Blair is an important element in our plan to shore up our capital structure and further evaluate opportunities for growth."
Zila, Inc. (Zila) is a specialty pharmaceutical company engaged towards prevention, detection and treatment of oral diseases with a focus on oral cancer. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
